Genelux Corp. (GNLX) - הכנסות ונפח מכירות

The development of Genelux Corporation (GNLX) is constrained by strict FDA regulations and the clinical testing stage. The GURU.Markets system provides the dynamics of the company's operating revenue from sales, where the value of 0.00 corresponds to the current metric. Revenues are based on the rollout of Olvi-Vec drugs for the therapy of solid tumors, while long-term profit relies on the licensing of viral technologies and patent protection.
פילוחים אנליטיים של חברת Genelux Corporation

Investors must strip away accounting distortions when assessing the issuer's real growth rates. The scientific potential of Genelux Corporation (GNLX) in solid tumor therapy provides the company with fundamental operational resilience. The daily revenue calculation in this sales time series excludes reporting manipulations, capturing the actual expansion of the business. This indicator's trend reflects the real quantitative expansion of its commercial presence. A stable upward trend confirms the market reliability of the biopharmaceutical brand.